Stockreport

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech SE - American Depositary Shares  (BNTX) 
PDF BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies [Read more]